Catalyst

Slingshot members are tracking this event:

Initial Results Expected from Phase 3 Lung Function Study for COPD

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
GSK

100%
INVA

100%

Additional Information

Additional Relevant Details GlaxoSmithKline plc and Innoviva (formerly Theravance) expect to release initial results from its Phase 3 global study (Salford Lung Study) with 'closed' triple combination treatment FF/UMEC/VI for COPD.  The co-primary endpoints are: to evaluate the effects of FF/UMEC/VI on lung function and health related quality of life compared with budesonide/formoterol after 24 weeks of treatment.  Initial results are expected in the first half of 2016.
http://investor.inva...
Slingshot Insights Explained
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Copd, Fulfil Study, Phase 3 Study